Structural and Functional Characterization of Falcipain-2, a Hemoglobinase from the Malarial Parasite Plasmodium falciparum*

Malaria is caused by protozoan erythrocytic parasites of the Plasmodium genus, with Plasmodium falciparum being the most dangerous and widespread disease-causing species. Falcipain-2 (FP-2) of P. falciparum is a papain-family (C1A) cysteine protease that plays an important role in the parasite life cycle by degrading erythrocyte proteins, most notably hemoglobin. Inhibition of FP-2 and its paralogues prevents parasite maturation, suggesting these proteins may be valuable targets for the design of novel antimalarial drugs, but lack of structural knowledge has impeded progress toward the rational discovery of potent, selective, and efficacious inhibitors. As a first step toward this goal, we present here the crystal structure of mature FP-2 at 3.1 Å resolution, revealing novel structural features of the FP-2 subfamily proteases including a dynamic β-hairpin hemoglobin binding motif, a flexible N-terminal α-helical extension, and a unique active-site cleft. We also demonstrate by biochemical methods that mature FP-2 can proteolytically process its own precursor in trans at neutral to weakly alkaline pH, that the binding of hemoglobin to FP-2 is strictly pH-dependent, and that FP-2 preferentially binds methemoglobin over hemoglobin. Because the specificity and proteolytic activity of FP-2 toward its multiple targets appears to be pH-dependent, we suggest that environmental pH may play an important role in orchestrating FP-2 function over the different life stages of the parasite. Moreover, it appears that selectivity of FP-2 for methemoglobin may represent an evolutionary adaptation to oxidative stress conditions within the host cell.

[1]  J. McKerrow,et al.  Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection , 1998, Journal of Experimental Medicine.

[2]  P. Rosenthal,et al.  Plasmodium falciparum: biochemical characterization of the cysteine protease falcipain-2'. , 2006, Experimental parasitology.

[3]  R. Read Improved Fourier Coefficients for Maps Using Phases from Partial Structures with Errors , 1986 .

[4]  P. Rosenthal,et al.  Folding of the Plasmodium falciparum Cysteine Protease Falcipain-2 Is Mediated by a Chaperone-like Peptide and Not the Prodomain* , 2002, The Journal of Biological Chemistry.

[5]  P. Rosenthal,et al.  Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. , 1999, Bioorganic & medicinal chemistry.

[6]  Michael G. Rossmann,et al.  An Algorithm for Automatic Indexing of Oscillation Images using Fourier Analysis , 1997 .

[7]  C. Hoogland,et al.  In The Proteomics Protocols Handbook , 2005 .

[8]  J F Gibrat,et al.  Surprising similarities in structure comparison. , 1996, Current opinion in structural biology.

[9]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Rotation Functions Biological Crystallography Likelihood-enhanced Fast Rotation Functions , 2003 .

[10]  David S Hartsough,et al.  Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease. , 2005, Bioorganic & medicinal chemistry.

[11]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[12]  P. Rosenthal,et al.  The Plasmodium falciparum cysteine protease falcipain-2 captures its substrate, hemoglobin, via a unique motif. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Chishti,et al.  Plasmodium falciparum cysteine protease falcipain-2 cleaves erythrocyte membrane skeletal proteins at late stages of parasite development. , 2002, Blood.

[14]  Oliver Zerbe,et al.  Structure–Activity Studies in a Family of β‐Hairpin Protein Epitope Mimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction , 2006 .

[15]  D. Turk,et al.  Crystal structure of cathepsin X: a flip-flop of the ring of His23 allows carboxy-monopeptidase and carboxy-dipeptidase activity of the protease. , 2000, Structure.

[16]  P. Rosenthal,et al.  Independent Intramolecular Mediators of Folding, Activity, and Inhibition for the Plasmodium falciparum Cysteine Protease Falcipain-2* , 2004, Journal of Biological Chemistry.

[17]  S. Müller Redox and antioxidant systems of the malaria parasite Plasmodium falciparum , 2004, Molecular microbiology.

[18]  B. O'connor,et al.  Proline specific peptidases. , 1997, Biochimica et biophysica acta.

[19]  P. Rosenthal,et al.  A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. , 1988, The Journal of clinical investigation.

[20]  Thomas C Terwilliger,et al.  Using prime-and-switch phasing to reduce model bias in molecular replacement. , 2004, Acta crystallographica. Section D, Biological crystallography.

[21]  Robert Huber,et al.  The refined 2.15 A X‐ray crystal structure of human liver cathepsin B: the structural basis for its specificity. , 1991, The EMBO journal.

[22]  D. Goldberg,et al.  Food vacuole plasmepsins are processed at a conserved site by an acidic convertase activity in Plasmodium falciparum. , 2003, Molecular and biochemical parasitology.

[23]  J. Thompson,et al.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. , 1997, Nucleic acids research.

[24]  I. G. Kamphuis,et al.  Structure of papain refined at 1.65 A resolution. , 1984, Journal of molecular biology.

[25]  D. Brömme,et al.  Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. , 2002, Chemical reviews.

[26]  R J Fletterick,et al.  A target within the target: probing cruzain's P1' site to define structural determinants for the Chagas' disease protease. , 2000, Structure.

[27]  M. Bogyo,et al.  Targeted disruption of Plasmodium falciparum cysteine protease, falcipain 1, reduces oocyst production, not erythrocytic stage growth , 2004, Molecular microbiology.

[28]  P. Rosenthal,et al.  Identification of three stage-specific proteinases of Plasmodium falciparum , 1987, The Journal of experimental medicine.

[29]  J T Palmer,et al.  Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. , 1991, The Journal of clinical investigation.

[30]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[31]  P. Evans,et al.  Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.

[32]  L. Goh,et al.  Homology modeling and mutagenesis analyses of Plasmodium falciparum falcipain 2A: implications for rational drug design. , 2004, Biochemical and biophysical research communications.

[33]  T. Ramya,et al.  Plasmepsin inhibitors: design, synthesis, inhibitory studies and crystal structure analysis. , 2005, The journal of peptide research : official journal of the American Peptide Society.

[34]  R J Fletterick,et al.  The crystal structure of cruzain: a therapeutic target for Chagas' disease. , 1995, Journal of molecular biology.

[35]  D. Goldberg,et al.  Plasmodium falciparum falcilysin: an unprocessed food vacuole enzyme. , 2003, Molecular and biochemical parasitology.

[36]  L. Goh,et al.  Characterization of amino acid variation at strategic positions in parasite and human proteases for selective inhibition of falcipains in Plasmodium falciparum. , 2005, Biochemical and biophysical research communications.

[37]  M. Leippe,et al.  Synthesis and antiplasmodial activity of a cysteine protease-inhibiting biotinylated aziridine-2,3-dicarboxylate , 2004, Biological chemistry.

[38]  P. Rosenthal,et al.  Comparison of Efficacies of Cysteine Protease Inhibitors against Five Strains of Plasmodium falciparum , 2001, Antimicrobial Agents and Chemotherapy.

[39]  Weltgesundheitsorganisation World malaria report , 2005 .

[40]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[41]  R. Huber,et al.  The 2.0 A crystal structure and substrate specificity of the KDEL-tailed cysteine endopeptidase functioning in programmed cell death of Ricinus communis endosperm. , 2004, Journal of molecular biology.

[42]  Matthew Bogyo,et al.  A Role for the Protease Falcipain 1 in Host Cell Invasion by the Human Malaria Parasite , 2002, Science.

[43]  R. Pickersgill,et al.  Structure of Monoclinic Papain at 1.60 Angstroms Resolution , 1994 .

[44]  R. Pickersgill,et al.  Structure of monoclinic papain at 1.60 Å resolution , 1992 .

[45]  Ashutosh Kumar Singh,et al.  Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. , 2001, The Biochemical journal.

[46]  A. Chishti,et al.  Ankyrin Peptide Blocks Falcipain-2-mediated Malaria Parasite Release from Red Blood Cells* , 2003, Journal of Biological Chemistry.

[47]  Anne Robert,et al.  From classical antimalarial drugs to new compounds based on the mechanism of action of artemisinin , 2001 .

[48]  J. Baird,et al.  Effectiveness of antimalarial drugs. , 2005, The New England journal of medicine.

[49]  Ashutosh Kumar Singh,et al.  Characterization of Native and Recombinant Falcipain-2, a Principal Trophozoite Cysteine Protease and Essential Hemoglobinase ofPlasmodium falciparum * , 2000, The Journal of Biological Chemistry.

[50]  Prashant Desai,et al.  Homology Modeling of Falcipain-2: Validation, De Novo Ligand Design and Synthesis of Novel Inhibitors , 2002, Journal of biomolecular structure & dynamics.

[51]  Eric Legrand,et al.  Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6 , 2005, The Lancet.

[52]  R. Stocker,et al.  Oxidative stress and protective mechanisms in erythrocytes in relation to Plasmodium vinckei load. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Khashayar Karimian,et al.  Thiol proteases: inhibitors and potential therapeutic targets. , 2006, Current medicinal chemistry.

[54]  Adam Godzik,et al.  The importance of alignment accuracy for molecular replacement. , 2004, Acta crystallographica. Section D, Biological crystallography.

[55]  Purnomo,et al.  Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. , 2002, The American journal of tropical medicine and hygiene.

[56]  D. Goldberg,et al.  Plasmodium falciparum Falcilysin , 2003, Journal of Biological Chemistry.

[57]  P. Rosenthal,et al.  Antimalarial Synergy of Cysteine and Aspartic Protease Inhibitors , 1998, Antimicrobial Agents and Chemotherapy.

[58]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[59]  K. Haldar,et al.  In Vitro Activity of Riboflavin against the Human Malaria Parasite Plasmodium falciparum , 2000, Antimicrobial Agents and Chemotherapy.

[60]  R J Fletterick,et al.  Structural determinants of specificity in the cysteine protease cruzain , 1997, Protein science : a publication of the Protein Society.

[61]  S. Hoffman,et al.  Primaquine therapy for malaria. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  R E Cachau,et al.  Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[63]  N. Rawlings,et al.  Evolutionary Lines of Cysteine Peptidases , 2001, Biological chemistry.

[64]  J. Thornton,et al.  Stereochemical quality of protein structure coordinates , 1992, Proteins.

[65]  D. Goldberg,et al.  Biosynthesis and Maturation of the Malaria Aspartic Hemoglobinases Plasmepsins I and II* , 1997, The Journal of Biological Chemistry.

[66]  A G Leslie,et al.  Biological Crystallography Integration of Macromolecular Diffraction Data , 2022 .

[67]  L. Brinen,et al.  Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain. , 2003, Bioorganic & medicinal chemistry.

[68]  S Muller The redox and antioxidant systems of Plasmodium falciparum , 2004 .

[69]  P. Rosenthal,et al.  Systematic optimization of expression and refolding of the Plasmodium falciparum cysteine protease falcipain-2. , 2001, Protein expression and purification.

[70]  P. Rosenthal,et al.  Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[71]  J. Frangos,et al.  Plasmodium berghei Resists Killing by Reactive Oxygen Species , 2005, Infection and Immunity.

[72]  P. Rosenthal,et al.  Biosynthesis, localization, and processing of falcipain cysteine proteases of Plasmodium falciparum. , 2005, Molecular and biochemical parasitology.